Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
Portfolio Pulse from
Can-Fite's partner, Vetbiolix, is advancing the clinical trial of Piclidenoson for canine osteoarthritis, targeting a $3.8 billion market. Can-Fite expects to earn $325 million in upfront payments and royalties over the next decade, assuming a 2029 launch.
March 20, 2025 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Can-Fite's partner Vetbiolix is advancing Piclidenoson trials for canine osteoarthritis, potentially leading to $325 million in revenue over the next decade, assuming a 2029 launch.
The news highlights a significant revenue opportunity for Can-Fite through its partnership with Vetbiolix. The potential $325 million in revenue from Piclidenoson, contingent on successful trials and a 2029 launch, is a positive development for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90